Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

Blood (2024) 143 (26): 2735–2748.

https://doi.org/10.1182/blood.2023021088

Published: 2024

Includes: Supplemental data

Journal Articles

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Blood (2024) 143 (17): 1738–1751.

https://doi.org/10.1182/blood.2023021952

Published: 2024

Includes: Supplemental data

Journal Articles

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Krauss, Arend von Stackelberg, Semjon Willier, Christina Peters, Tobias Feuchtinger

Blood (2023) 142 (Supplement 1): 2135.

https://doi.org/10.1182/blood-2023-190117

Published: 2023

Journal Articles

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4350.

https://doi.org/10.1182/blood-2023-179306

Published: 2023

Journal Articles

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Blood (2023) 142 (Supplement 1): 825.

https://doi.org/10.1182/blood-2023-181524

Published: 2023

Journal Articles

Phenotypic Drug Response Profiling Identifies Asparaginase-Based Synergistic Combinations for Very High Risk Acute Lymphoblastic Leukaemia

Jasmeet Sidhu, Fabio D. Steffen, Iria Anne Jimenez, Yun Huang, Kerstin K. Rauwolf, Arijit Chakraborty, Shekhar Krishnan, Vaskar Saha, Beat Bornhauser, Jean-Pierre Bourquin

Blood (2023) 142 (Supplement 1): 417.

https://doi.org/10.1182/blood-2023-172885

Published: 2023

Journal Articles

Delayed Intensification Including Venetoclax and Bortezomib Prolongs Survival in Very High Risk Acute Lymphoblastic Leukaemia

Jasmeet Sidhu, Arijit Chakraborty, Parag Das, Manash Pratim Gogoi, Tanima Dey, Fabio D. Steffen, Sangramjit Basu, Debdutta Ganguli, Debjani Ghosh, Niharendu Ghara, Subhajit Kundu, Abhirupa Kar, Beat Bornhauser, Jean-Pierre Bourquin, Vaskar Saha, Shekhar Krishnan

Blood (2023) 142 (Supplement 1): 4244.

https://doi.org/10.1182/blood-2023-185989

Published: 2023

Journal Articles

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

Blood (2023) 142 (Supplement 1): 730.

https://doi.org/10.1182/blood-2023-181593

Published: 2023

Journal Articles

ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010

Blood (2022) 140 (Supplement 1): 3247–3249.

https://doi.org/10.1182/blood-2022-166234

Published: 2022

Journal Articles

IKZF1 Deletions Induce Resistance to AraC in BCP-ALL Reversible By CDK8/19 Inhibition

Britt M T Vervoort, Miriam Butler, Dorette van Ingen Schenau, Vincent H.J. van der Velden, Beat Bornhauser, Jean-Pierre Bourquin, Laurens T van der Meer, Frank N van Leeuwen

Blood (2022) 140 (Supplement 1): 3465–3466.

https://doi.org/10.1182/blood-2022-162246

Published: 2022

Journal Articles

The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Lennart Lenk, Irène Baccelli, Dorothee Winterberg, Anna Dietterle, Frédérique Corallo, Julien Taurelle, Emma Narbeburu, Anna Laqua, Beat Bornhauser, Jean-Pierre Bourquin, Fotini Vogiatzi, Martin Schrappe, Gunnar Cario, Monika Brüggemann, Nicolas Poirier, Denis Martin Schewe

Blood (2022) 140 (Supplement 1): 1045–1047.

https://doi.org/10.1182/blood-2022-162261

Published: 2022

Journal Articles

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

Blood (2022) 140 (1): 45–57.

https://doi.org/10.1182/blood.2021014485

Published: 2022

Includes: Supplemental data

Journal Articles

BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway

Miriam Butler, Dorette S. van Ingen Schenau, Jiangyan Yu, Silvia Jenni, Maria P. Dobay, Rico Hagelaar, Britt M. T. Vervoort, Trisha M. Tee, Fieke W. Hoff, Jules P. Meijerink, Steven M. Kornblau, Beat Bornhauser, Jean-Pierre Bourquin, Roland P. Kuiper, Laurens T. van der Meer, Frank N. van Leeuwen

Blood (2021) 138 (23): 2383–2395.

https://doi.org/10.1182/blood.2021011787

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children's Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients

Blood (2021) 138 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2021-145709

Published: 2021

Journal Articles

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia

Blood (2021) 138 (9): 773–784.

https://doi.org/10.1182/blood.2020010510

Published: 2021

Includes: Supplemental data

Journal Articles

Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO)

Franco Locatelli, MD PhD, Gerhard Zugmaier, Noemi Mergen, MD, Peter Bader, MD, Sima Jeha, MD, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD, Benoit Brethon, MD, Claudia Rössig, William Kormany, MD, Puneeth Viswagnachar, Christiane Chen-Santel

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-141336

Published: 2020

Journal Articles

Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement

Elad Jacoby, MD, Sara Ghorashian, FRCPath, PhD, Britta Julia Vormoor, MD, Barbara De Moerloose, MD, Nicole Bodmer, Michael Maschan, MD, Asaf David Yanir, MD, Bella Bielorai, MD, Srdan Rogosic, Olga Molostova, MD, Claudia Rossig, Amos Toren, MD PhD, Arend von Stackelberg, MD, Jean-Pierre Bourquin, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141940

Published: 2020

Journal Articles

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Fotini Vogiatzi, PhD, Kristina Müller, Dorothee Winterberg, Thies Rösner, PhD, Lennart Lenk, PhD, Gunnar Cario, MD PhD, Martin Schrappe, MDPhD, Andreas E. Kulozik, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140270

Published: 2020

Journal Articles

Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141774

Published: 2020

Journal Articles

The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL

Jordy C.G. Van Der Zwet, MD, Jessica G.C.A.M. Buijs-Gladdines, Valentina Cordo', MSc, Donna Debets, MSc, Willem K. Smits, Zhongli Chen, MSc, Jelle Dylus, Guido Zaman, PhD, Maarten Altelaar, PhD, Koichi Oshima, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Jan Cools, PhD, Adolfo A. Ferrando, MD PhD, Josef Vormoor, MD PhD, Rob Pieters, MDPhDMSc, Britta Julia Vormoor, MD, Jules P.P. Meijerink, PhD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-139305

Published: 2020

NARROW

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Phenotypic Drug Response Profiling Identifies Asparaginase-Based Synergistic Combinations for Very High Risk Acute Lymphoblastic Leukaemia

Delayed Intensification Including Venetoclax and Bortezomib Prolongs Survival in Very High Risk Acute Lymphoblastic Leukaemia

Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial

IKZF1 Deletions Induce Resistance to AraC in BCP-ALL Reversible By CDK8/19 Inhibition

The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia

Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO)

Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only